Could a common constipation drug help diabetics?
NCT ID NCT03119584
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether linaclotide (Linzess) can improve bowel movement frequency in people with type 2 diabetes who have chronic constipation. About 23 participants will receive either the drug or a placebo for two weeks, then switch after a break. The goal is to see if the drug safely increases spontaneous bowel movements.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
linaclotide (Linzess)
What this could lead to
If it works, this could provide a safe, effective option for relieving chronic constipation in people with type 2 diabetes.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The drug may cause side effects like diarrhea or abdominal pain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Texas Tech University Health Sciences Center
El Paso, Texas, 79905, United States